Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
32.00    -0.75 (-2.29%)
Bid:
31.00
Ask:
33.00
Spread: 2.00 (6.452%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Trading Update

16 Apr 2013 07:00

RNS Number : 4075C
Ilika plc
16 April 2013
Β 

ο»Ώ

Β 

Ilika plc

("Ilika" or the "Company")

Β 

Trading Update

Β 

Ilika (AIM: IKA), the advanced cleantech materials discovery company, provides the following trading update for the financial year ending 30 April 2013.

Β 

Operational Review

The main focus of Ilika's technology development remains on its solid-state lithium-ion battery technology, for which it successfully raised funds in April 2012. Progress remains on schedule with further tests on the prototype cells being conducted to ensure that the technology is as robust as possible and to continue to improve performance. It is currently filing additional intellectual property in the area to protect its proprietary position.

Β 

Following the announcement in December 2012, that the Company had received the grant of a key patent covering its novel fuel cell catalyst compositions in the US, Ilika has submitted positive cell performance data and material samples for evaluation by select automotive manufacturers based primarily in the US and Japan. Furthermore, Ilika's development partner in Taiwan has now successfully manufactured the catalyst material, which is a critical component of the battery cell, to Ilika's specification at the kilogram scale. This development progress ensures that the industrial production process can be readily transferred to any volume manufacturing partner.

Β 

Relationships with our other development partners and end customers across our other material development programmes remain strong, with announcements regarding renewals with its largest customer having been made in December 2012 and February 2013. Further such renewals are expected to continue in the coming financial year.

Β 

Financial Review

Despite significant operational progress across all its IP development programmes, the Company has experienced order delays with three unrelated contracts. Two of the contracts are from new customers in the US and the third is from a new customer in Europe. These are in the area of battery technology and structural materials. All three contracting processes are still live and the Company will update the market as soon as further news is available.

Β 

As a direct consequence of these delays, it is expected that revenue for the year ending 30 April 2013 will be approximately Β£1.1m (2012: Β£2.0m). This reduction in revenue expectation is directly reflected in a reduced EBITDA expectation (Earnings before Interest, tax, depreciation, amortisation and share based payments), which will be a loss of approximately Β£3.2m (2012: Β£1.8m). The loss before tax is expected to be approximately Β£4m (2012: Β£2.8m).

Β 

Following the successful expansion of facilities and infrastructure, cash balances will amount to approximately Β£1.8m at 30 April 2013 (2012: Β£5.3m). Overheads have been reduced following the successful disposal of Ilika's wound care operations, as announced in December, and costs will continue to be closely managed going forward.

Β 

Outlook

Budgeting in the next financial year will reflect the more conservative deal conversion rates and longer timelines experienced in this financial year. Consequently, lower sales are forecast relative to previous expectations, but are underpinned by mature sales prospects.

Β 

In the coming financial year, the Company expects to reap the benefits of the infrastructure and development investments already made.

Β 

Ilika expects to announce its audited full year results for the year ended 30 April 2013 on or around 15 July 2013.

Β 

Commenting on the Trading Update, Graeme Purdy, Ilika's Chief Executive, said: "We are disappointed with the delays in acquiring new customers that are impacting this year's financial performance. However, we are encouraged by the significant progress made in the development of our solid state battery technology and the initial reception given by the international automotive industry to our low cost fuel cell catalyst. Feedback from our customers is indicating sustained demand for innovation in both battery and fuel cell technologies to reduce the cost point for energy storage and motive power. This year has provided a strong springboard for further commercialisation milestones and revenue growth going forward. Further guidance will be given with our annual results in July."

Β 

For more information contact:

Β 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

Β 

Β 

Β 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan, Nominated Adviser

Β 

James Black, Corporate Broking

Β 

Β 

Β 

Walbrook PR Ltd

Tel: 020 7933 8780 or ilika@walbrookpr.com

Paul McManus

07980 541 893

Paul Cornelius

07827 879 460

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTSFAFWIFDSEIL
Date   Source Headline
21st May 20267:00 amRNSIlika Trading Update and Notice of Results
10th Apr 20264:01 pmRNSCollaboration with Brompton Bicycles
18th Mar 20267:00 amRNSPositive Feedback on Safety of Goliath Cells
10th Mar 20267:00 amRNSFirst Commercial Delivery to Cirtec Medical
24th Feb 202610:21 amRNSAward of Share Options
19th Feb 20267:00 amRNS-RIlika at Yellowstone Investor Evening: Replacement
22nd Jan 20267:00 amRNSHalf-year Financial Report
21st Jan 20267:00 amRNSIlika Secures Stereax Electrode Order from Cirtec
18th Dec 20257:00 amRNSInitial Stereax M300 Shipments
11th Dec 20257:00 amRNSIlika Ships 10Ah Goliath Battery Prototypes
20th Nov 20257:00 amRNSTrading Update & Notice of Half-Year Results
21st Oct 20257:00 amRNSCommissioning Complete for Goliath Pilot Line
1st Oct 202512:00 pmRNSExercise of Options and Total Voting Rights
23rd Sep 20253:43 pmRNSResult of AGM & Award of Executive Share Options
22nd Sep 20257:00 amRNSStart of Primed Solid-State Battery Programme
28th Aug 20257:00 amRNSNotice of AGM and Posting of Annual Report
18th Aug 20257:00 amRNSStereax Battery Milestone at Cirtec Medical
17th Jul 20258:56 amRNSHolding(s) in Company
17th Jul 20257:00 amRNSFinal Results
15th Jul 20257:00 amRNSAward of Government Grant Funding
11th Jun 20252:09 pmRNSNotice of Results
4th Jun 20252:14 pmRNSHolding(s) in Company
3rd Jun 20251:57 pmRNSHolding(s) in Company
28th May 20256:00 pmRNSResult of Oversubscribed Retail Offer
22nd May 20252:16 pmRNSRetail Offer for up to £0.5 million
22nd May 20251:53 pmRNSResult of Placing & Director Subscription
21st May 20255:14 pmRNSProposed Capital Raise
7th May 202510:03 amRNS-RIlika announces 2025 Investor Day
1st May 20257:00 amRNSGoliath P1 Cells Validated by Customer Testing
15th Apr 20257:00 amRNSGoliath Battery Achieves Scale-up Milestone
6th Mar 20257:00 amRNSGoliath Development Progress
27th Feb 20257:00 amRNSAward & Exercise of Share Options
6th Feb 20253:49 pmRNSHolding(s) in Company
5th Feb 20257:00 amRNSGoliath Scale-up Progress
21st Jan 20257:00 amRNSHalf-year Results
9th Jan 20257:00 amRNSStereax Equipment Commissioning Completed
19th Dec 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker
22nd Nov 20242:18 pmRNSAIM Rule 17 Schedule 2(g) Update
20th Nov 20247:00 amRNSGoliath D6 milestone reached
15th Nov 20247:00 amRNSTrading Update & Notice of Half-Year Results
10th Oct 20241:49 pmRNSHolding(s) in Company
3rd Oct 20247:00 amRNSFurther Goliath Technical Milestone Achieved
29th Aug 20247:00 amRNSPosting of Annual Report and Notice of AGM
11th Jul 20247:00 amRNSFinal Results
2nd Jul 20247:00 amRNSKey Technology Validation Milestone
1st Jul 20247:00 amRNSNominated Adviser and Joint Broker
31st May 20242:29 pmRNSHolding(s) in Company
29th May 202411:52 amRNSResults of General Meeting Open Offer and TVR
22nd May 20247:00 amRNSKey Goliath Technology Validation Milestone
16th May 20247:00 amRNSTrading Update, Notice of Results & Presentations

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.